KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EPS (Weighted Average and Diluted) (2018 - 2025)

Esperion Therapeutics' EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at $0.32 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 390.91% year-over-year to $0.32; the TTM value through Dec 2025 reached -$0.11, up 56.0%, while the annual FY2025 figure was -$0.11, 60.71% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.32 in Q4 2025 per ESPR's latest filing, up from -$0.16 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.34 in Q1 2024 to a low of -$3.5 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.77, with a median of -$0.48 recorded in 2023.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 390.91% in 2025 against a maximum downside of 161.76% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.53 in 2021, then skyrocketed by 51.63% to -$0.74 in 2022, then soared by 32.43% to -$0.5 in 2023, then surged by 78.0% to -$0.11 in 2024, then surged by 390.91% to $0.32 in 2025.
  • Per Business Quant, the three most recent readings for ESPR's EPS (Weighted Average and Diluted) are $0.32 (Q4 2025), -$0.16 (Q3 2025), and -$0.06 (Q2 2025).